Core Insights - The company launched the "Chenpi Culture Festival" in Guangzhou, themed "Sailing Against the Wind, Living Forever," and released the "Chenpi Health '14th Five-Year' Strategic Plan" [1] - The company has established a solid industrial barrier by leveraging authentic resources from the core production area in Jiangmen, Guangdong [1] - The company has developed a variety of products around the Chenpi health industry, including aged Chenpi, Chenpi tea, medicinal pastes, and health foods to meet diverse consumer needs [1] Group 1 - The company has created a GAP demonstration planting base in the core production area, ensuring the authenticity and quality stability of raw materials through standardized management [2] - The company combines traditional aging techniques with modern technology, establishing a digital platform for the Chenpi industry park in collaboration with China Telecom, enabling real-time data access via blockchain [2] - The company aims to transform "data elements" into "gold elements" for farmers' income through blockchain traceability and AI identification of aging levels [2] Group 2 - The company has introduced the "Changsheng" cultural IP to engage young people with traditional Chinese medicine through immersive activities [2] - The Chen Li Ji Traditional Chinese Medicine Museum in Guangzhou serves as a cultural hub, offering innovative products like Chenpi coffee and health teas [2] - The company actively promotes the integration of the Chenpi industry with cultural tourism, enhancing local dining and accommodation sectors through events at the Chenpi Culture Festival [2]

Group 1 - The core viewpoint of the news highlights the strong performance of the Traditional Chinese Medicine (TCM) sector, driven by supportive government policies aimed at innovation and industrial transformation [1][2] - The Shanghai government has issued a document encouraging collaboration among medical institutions, research units, and pharmaceutical companies to create platforms for TCM innovation and industrial transformation [1] - The document supports the development of major TCM varieties and the secondary development of classic varieties, as well as the establishment of mechanisms for collecting and organizing human experience data for drug registration [1] Group 2 - China Galaxy Securities anticipates that policy-driven changes will continue to propel the pharmaceutical industry towards innovation and upgrades, with a focus on finding incremental opportunities in niche markets [2] - The report indicates that domestic innovative drugs are expected to yield results, with several second-generation I/O drugs and ADCs entering phase three clinical trials, which is promising for future developments [2] - The TCM prescription drug market is facing clinical re-evaluation, which may reshape the market landscape and potentially lead to a turning point in TCM gross margins [2] Group 3 - The TCM ETF closely tracks the Zhongzheng TCM Index, which selects listed companies involved in TCM production and sales to reflect the overall performance of TCM concept stocks [2] - As of October 31, 2025, the top ten weighted stocks in the Zhongzheng TCM Index account for 54.92% of the index, including companies like Yunnan Baiyao and Tongrentang [2]

Core Viewpoint - The article discusses the strategic transformation of Chen Li Ji, a 425-year-old traditional Chinese medicine brand, focusing on its integration of Chen Pi (dried tangerine peel) into the health industry, digital transformation, and rural revitalization efforts [1][2][4]. Group 1: Strategic Initiatives - Chen Li Ji launched the Chen Pi Cultural Festival themed "Sailing Against the Wind, Living Forever," marking its 425th anniversary and announcing the "Chen Pi Health" strategic plan [3][4]. - The company aims to leverage Chen Pi as a pivotal element to drive its growth in the health industry, digital transformation, and rural revitalization [5][12][54]. Group 2: Industry Context - The Chen Pi industry is experiencing unprecedented growth opportunities, with the New Hui district reporting a planting area of approximately 143,000 acres and a fresh fruit output of 180,000 tons in 2024 [16][17]. - The total output value of the Chen Pi industry is estimated at 26.018 billion yuan, providing employment and income increases for over 70,000 people, with farmers seeing an average income increase of about 22,000 yuan [18]. Group 3: Policy Support - The Chinese government has issued policies to promote the inheritance and innovation of traditional Chinese medicine, which supports the development of the Chen Pi industry [20][21][28]. - Chen Li Ji's new Chen Pi industrialization planting base was included in the second batch of Guangdong Province's traditional Chinese medicine industrialization base list in 2021, reflecting direct benefits from these policies [28][30]. Group 4: Consumer Trends - There is a notable shift in consumer demographics towards younger generations, with individuals under 35 years old making up 35.9% of the traditional health demand group [33]. - The health service industry is projected to reach a total scale of 16 trillion yuan by 2030, with the health and wellness market already valued at 708.2 billion yuan in 2022 and continuing to grow [34][35]. Group 5: Product Development - Chen Li Ji has expanded its product line from traditional Chinese medicine to include various health products such as aged Chen Pi, Chen Pi tea, and other health foods, catering to modern consumer preferences [54][78]. - The company has established a digital platform for the Chen Pi industry, integrating blockchain technology for traceability and quality assurance, addressing long-standing trust issues in the industry [68][76]. Group 6: Cultural Integration - Chen Li Ji is promoting cultural integration through events like the Chen Pi Cultural Festival and creative cultural projects, transforming traditional Chen Pi culture into appealing elements for younger consumers [80][83]. - The company has created an immersive cultural experience at its museum in Guangzhou, allowing urban consumers to engage with Chen Pi culture in a familiar setting [86][90].

Core Insights - The article highlights the successful development of the 1906 Industrial Park in the Liwan District of Guangzhou, which has achieved over 90% occupancy and revitalized the urban landscape by attracting technology and cultural enterprises [1] - The Liwan District has initiated a three-year action plan to enhance industrial land utilization, aiming to create modern industrial parks that support the "1283" modern industrial system [2][4] - The district is focusing on strategic industry clusters, particularly in laser and additive manufacturing, to drive economic growth and innovation [6][10] Group 1: Industrial Development - Liwan District has completed planning optimization for three industrial clusters, providing 40.32 hectares of industrial land and 1.3 million square meters of industrial space [2] - The district aims to construct 6 million square meters of quality industrial space by 2026, including high-standard industrial plants and commercial spaces [4][12] - The "百千万工程" (Hundred-Thousand-Ten-Thousand Project) is being implemented to promote industrial development and attract new enterprises [1][4] Group 2: Strategic Industry Focus - Laser and additive manufacturing is identified as a key strategic industry cluster, with the district hosting a 3D printing innovation exhibition to showcase the entire industry chain [6][10] - The district has established a 10 billion yuan industrial development fund to support the growth of the laser and additive manufacturing sector [7][10] - Liwan is collaborating with various universities and research institutions to enhance talent and technology resources for the industry [10][11] Group 3: Economic Performance - The Liwan District's laser and additive manufacturing cluster is projected to reach a scale of nearly 6 billion yuan, with an 8% year-on-year growth [13] - The district achieved a 4.2% increase in industrial output value in the first three quarters of 2025, ranking fourth in the city [13] - The industrial technological transformation investment growth rate reached 71.6%, the highest in the city [13]

Core Viewpoint - The Chinese traditional medicine sector is experiencing a positive trend, with the Zhongzheng Traditional Chinese Medicine Index showing an increase, driven by rising flu cases and the performance of key stocks in the industry [1][2]. Group 1: Market Performance - As of November 24, 2025, the Zhongzheng Traditional Chinese Medicine Index (930641) rose by 0.68%, with a one-year dividend yield of 3.18% [1]. - Key component stocks such as Jiaying Pharmaceutical (002198) increased by 4.48%, Zhongsheng Pharmaceutical (002317) by 2.86%, and others also showed positive growth [1]. - The Zhongzheng Traditional Chinese Medicine ETF (159647) increased by 0.40%, with the latest price at 1 yuan [1]. Group 2: Flu Trends and Impact - The National Influenza Center reported that the ILI% in southern hospitals was 5.5%, up from 4.6% the previous week, and higher than the same period in 2022 and 2024 [1]. - Northern hospitals reported an ILI% of 6.1%, also higher than the previous week and exceeding levels from the last three years [1][2]. - The rising flu positivity rates in both southern and northern regions are attributed to lower immunity against the H3N2 strain and an earlier onset of the flu season this year [2]. Group 3: Industry Outlook - The flu season for 2025-2026 is expected to peak higher than the previous year, leading to increased demand for respiratory infection-related products [2]. - The traditional Chinese medicine sector is anticipated to face short-term performance pressure but is expected to benefit from policies related to centralized procurement and basic medicine, as well as innovation-driven growth [2]. - The top ten weighted stocks in the Zhongzheng Traditional Chinese Medicine Index account for 54.92% of the index, indicating a concentrated market structure [3].

2020-2025年1-9月中国中成药产量统计图 数据来源：国家统计局，智研咨询整理 知前沿，问智研。智研咨询是中国一流产业咨询机构，十数年持续深耕产业研究领域，提供深度产业研 究报告、商业计划书、可行性研究报告及定制服务等一站式产业咨询服务。专业的角度、品质化的服 务、敏锐的市场洞察力，专注于提供完善的产业解决方案，为您的投资决策赋能。 上市企业：云南白药（000538）,同仁堂（600085）,片仔癀（600436）,白云山（600332）,太极集团 （600129）,东阿阿胶（000423）,九芝堂（000989）,贵州百灵（002424）,葵花药业（002737）,吉林敖 东（000623） 相关报告：智研咨询发布的《2026-2032年中国中成药行业发展形势分析及产业前景规划报告》 根据国家统计局数据显示：2025年9月中国中成药产量为16.9万吨，同比增长2.4%；2025年1-9月中国中 成药累计产量为132.2万吨，累计下降8.3%。 ...

Group 1 - The event attracted nearly 100,000 spectators, showcasing the significance of the competition and the farewell of the athlete Su Bingtian [2] - The integration of 5G-A and AI technology significantly improved communication efficiency, reducing video sending time from over 30 seconds to under 5 seconds, and increasing the smoothness of messaging to 98% [2] - State-owned enterprises played a crucial role in supporting the event, leveraging the advantages of the Guangdong-Hong Kong-Macao Greater Bay Area to integrate various sectors such as sports, tourism, and hospitality [2][3] Group 2 - The Guangzhou University Town sports center completed the first zero-carbon sports venue renovation project in the country, featuring over 1,000 square meters of solar panels and achieving a 53% energy-saving rate [3] - The event marked the first time no new large venues were constructed, emphasizing the focus on sustainable practices [3] - The renovated climbing venue will serve over one million citizens annually, transforming into an open climbing park post-event [3] Group 3 - The "Zhanmeng 3" table tennis table introduced innovative structures and multimedia equipment, enhancing stability and precision for the matches [4] - A specialized technical team provided over 22,000 pieces of equipment for shooting events, ensuring high standards for performance and accuracy [4] Group 4 - The first cross-border marathon event took place, with 71 athletes participating, showcasing the integration of technology for seamless operations [5] - The use of a "super 5G-A channel" ensured zero delays for athletes and support vehicles, highlighting the technological advancements in event management [5] - Various companies implemented smart technologies for efficient venue management and enhanced visitor experiences [5] Group 5 - The Guangdong cultural and sports industry is experiencing a new wave of development opportunities, with state-owned enterprises playing a pivotal role in stimulating cultural and sports consumption [6][8] - The retail sales of sports and entertainment products in Guangdong increased by 32.2% year-on-year in the first three quarters, indicating a growing market [8] - The establishment of the Guangzhou Cultural and Sports Industry Development Group aims to create a professional, market-oriented, and international development blueprint for the industry [8] Group 6 - Various state-owned enterprises are developing cultural products that integrate traditional elements with modern sports, creating over 60 licensed products [7] - The focus on local cuisine and cultural heritage through special food boxes aims to leverage the event's popularity to expand market reach [7] - Upgrades to hospitality services in the region are designed to enhance the visitor experience during the event [7]

Core Viewpoint - The company, Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd., is set to hold a Q3 2025 performance briefing on November 28, 2025, to discuss its operational results and financial status with investors [2][3]. Group 1: Meeting Details - The performance briefing will take place on November 28, 2025, from 16:00 to 17:00 [4]. - The meeting will be held at the Shanghai Stock Exchange Roadshow Center, accessible via the website: https://roadshow.sseinfo.com/ [4]. - The format of the meeting will be an interactive online session, allowing for real-time communication with investors [3][4]. Group 2: Participation Information - Investors can participate in the briefing by logging into the Shanghai Stock Exchange Roadshow Center on the scheduled date and time [5]. - Questions can be submitted by investors from November 21, 2025, to November 27, 2025, through the "Pre-Question Collection" section on the website or via the company's email [5]. - The company will address commonly asked questions during the briefing [5]. Group 3: Attendees - Key personnel attending the briefing include the Executive Director and General Manager, Mr. Li Hong, Independent Director Mr. Huang Longde, Board Secretary Ms. Huang Xuezheng, and Chief Financial Officer Ms. Liu Fei [4].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條而作出的。 茲刊載廣州白雲山醫藥集團股份有限公司（「本公司」）在上海證券交易所網站(www.sse.com.cn)刊登的 本公司關於召開2025年第三季度業績說明會的公告之中文全文，僅供參考。 廣州白雲山醫藥集團股份有限公司 董事會 中國廣州，2025年11月20日 於本公告日，本公司董事會成員包括執行董事李小軍先生、陳傑輝先生、程寧女士、程洪進先生、 唐和平先生與黎洪先生，及獨立非執行董事陳亞進先生、黃民先生、黃龍德先生與孫寶清女士。 证券代码：600332 证券简称：白云山 公告编号：2025-080 广州白云山医药集团股份有限公司 关于召开 2025 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 二、 说明会召 ...

Group 1 - The Artemisinin concept index rose by 0.31%, ranking 10th among concept sectors, with three stocks increasing in value, including Delong Huineng, Rundu Co., and Haizheng Pharmaceutical, which rose by 4.35%, 0.87%, and 0.19% respectively [1] - The leading decliners in the sector included Fosun Pharma, New Hecheng, and Baiyunshan, which fell by 1.23%, 0.36%, and 0.34% respectively [1] Group 2 - The main capital flow analysis indicates a net outflow of 176 million yuan from the Artemisinin concept sector, with only one stock, Delong Huineng, experiencing a net inflow of 8.0428 million yuan [2] - The capital flow rankings for the Artemisinin concept show that Delong Huineng had a trading volume of 4.35% and a turnover rate of 13.19%, while other stocks like Kunming Pharmaceutical Group and Rundu Co. had net outflows of 1.72 million yuan and 3.06 million yuan respectively [2][3]